Donanemab became the second Alzheimer's drug that targets causative deposited plaque in the brain to win the coverage after ...

There is a lot of outrage that the new Alzheimer’s drug donanemab is being refused on the NHS. But there are good reasons for ...

Seeking ways to improve the safety of anti-amyloid antibodies, John Sims of Eli Lilly & Company presented a simple option to do so for donanemab at this year’s Clinical Trials on Alzheimer’s Disease ...

The drug Donanemab has been found to slow the progression of Alzheimer’s disease. Despite this is has been rejected for widespread use in the health service in England after the health spending ...

Donanemab has been hailed as 'a new hope' in the fight against dementia, after studies showed it slowed the memory-robbing illness in its early stages. And today it got the green light from UK ...

Peter Almond finished a trial for Donanemab in September having been on the drug for three years. Donanemab is one of the new “disease modifying” treatments for Alzheimer’s disease ...

Donanemab can slow the progression of Alzheimer’s disease. But what is the drug and how does it work? Here your questions on the latest development in Alzheimer’s research are answered.

The UK’s drugs regulator – the MHRA – has approved the Alzheimer’s drug donanemab, but it won’t be available on the NHS.

A retired journalist who took part in the clinical trial for the new Alzheimer’s drug has described how he feels “as normal ...

The costs of providing donanemab, including regular infusions and intensive monitoring for serious side effects, balanced against the relatively small benefit it provides to patients, means it cannot ...